Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELL | P14151 | 1/20 | 0.50 |
| ▸ | SELP | P16109 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | RAD52 | P43351 | 1/20 | 0.35 |
| ▸ | TERT | O14746 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11097025 | 0.83 | ALDH1A1 (0.50) | ALDH1A1HPGDTERTMAPTHSD17B10 | |
| SCHEMBL7032709 | 0.75 | SELL (0.50) | SELLSELPHDAC1PIK3CAALDH1A1 | |
| SCHEMBL924425 | 0.75 | SELL (0.62) | SELLSELPHDAC1PIK3CAALDH1A1 | |
| SCHEMBL1699097 | 0.71 | SELL (0.46) | SELLSELPHDAC1PIK3CAALDH1A1 | |
| SCHEMBL18732063 | 0.71 | SELL (0.46) | SELLSELPHDAC1PIK3CAALDH1A1 | |
| SCHEMBL18732057 | 0.71 | SELL (0.46) | SELLSELPHDAC1PIK3CAALDH1A1 | |
| SCHEMBL29373601 | 0.71 | ALDH1A1 (0.57) | SELLSELPHDAC1PIK3CAALDH1A1 | |
| SCHEMBL338346 | 0.71 | ALDH1A1 (0.57) | SELLSELPHDAC1PIK3CAALDH1A1 | |
| SCHEMBL3333046 | 0.70 | SELL (0.64) | SELLSELPHDAC1PIK3CAALDH1A1 | |
| SCHEMBL17459215 | 0.70 | SELL (0.45) | SELLSELPHDAC1PIK3CAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2125712-B1 | NOVEL PROTEIN KINASE MODULATORS AND THERAPEUTIC USES THEREOF | NOVOTYR THERAPEUTICS LTD (IL) | 2014-07-23 | — | — | EP | disclosed |
| US-20120083528-A1 | NOVEL PROTEIN KINASE MODULATORS AND THERAPEUTIC USES THEREOF | NOVOTYR THERAPEUTICS LTD. (IL) | 2012-04-05 | — | — | US | disclosed |
| US-8058309-B2 | Protein kinase modulators and therapeutic uses thereof | NOVOTYR THERAPEUTICS LTD. (IL) | 2011-11-15 | — | — | US | disclosed |
| US-20100056635-A1 | NOVEL PROTEIN KINASE MODULATORS AND THERAPEUTIC USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2010-03-04 | — | — | US | disclosed |
| EP-2125712-A1 | NOVEL PROTEIN KINASE MODULATORS AND THERAPEUTIC USES THEREOF | Novotyr Therapeutics Ltd. (IL) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008068751-A1 | NOVEL PROTEIN KINASE MODULATORS AND THERAPEUTIC USES THEREOF | NOVOTYR THERAPEUTICS LTD. (IL) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083528-A1 | NOVEL PROTEIN KINASE MODULATORS AND THERAPEUTIC USES THEREOF | PTK2B, LTK, MAP3K20 | SELL 3563/4885SELP 2780/4885HDAC1 2475/4885 |
| US-20100056635-A1 | NOVEL PROTEIN KINASE MODULATORS AND THERAPEUTIC USES THEREOF | PTK2B, LTK, FRK | SELL 3271/4885SELP 2549/4885HDAC1 2568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.